for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

argenx SE

ARGX.BR

Latest Trade

115.40EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

54.30

 - 

135.70

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
115.40
Open
--
Volume
--
3M AVG Volume
2.01
Today's High
--
Today's Low
--
52 Week High
135.70
52 Week Low
54.30
Shares Out (MIL)
38.11
Market Cap (MIL)
4,398.72
Forward P/E
-37.95
Dividend (Yield %)
--

Next Event

argenx SE Annual Shareholders Meeting

Latest Developments

More

Argenx H1 Operating Loss Widens to 54.5 Million

Argenx Plans To Launch A Phase 2 Trial In CIDP Before End Of 2019

Argenx Announces Pipeline Expansion And “Argenx 2021” Vision

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About argenx SE

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Industry

Biotechnology & Drugs

Contact Info

Willemstraat 5

+31.76.3030488

http://www.argen-x.com

Executive Leadership

Peter K. M. Verhaeghe

Non-Executive Independent Chairman

Tim Van Hauwermeiren

Chief Executive Officer, Co-Founder, Executive Director

Werner Lanthaler

Non-Executive Independent Vice Chairman

Eric Castaldi

Chief Financial Officer

Keith Woods

Chief Operating Officer

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (EUR)

2016

-1.140

2017

-1.141

2018

-1.990

2019(E)

-3.075
Price To Earnings (TTM)
--
Price To Sales (TTM)
93.38
Price To Book (MRQ)
6.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.72
LT Debt To Equity (MRQ)
0.55
Return on Investment (TTM)
-14.79
Return on Equity (TTM)
-13.39

Latest News

AbbVie doubles down on cancer project with biotech group Argenx

Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros

* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)

* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma

* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod

* TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Argenx ‍Announces Orphan Drug Designation For Argx-113 For Treatment Of Myasthenia Gravis In Europe​

* ANNOUNCES ORPHAN DRUG DESIGNATION FOR ARGX-113 FOR TREATMENT OF MYASTHENIA GRAVIS IN EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Argenx Reports Fourth Quarter Business Update And Full Year 2017 Financial Results

* ARGENX REPORTS FOURTH QUARTER BUSINESS UPDATE AND FULL YEAR 2017 FINANCIAL RESULTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Argenx FY Total Operating Income Rises To 41.3 Million Euros

* FY REVENUE EUR 36.4 MILLION VERSUS EUR 14.7 MILLION YEAR AGO

BRIEF-Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS

* HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS

BRIEF-Argenx announces launch of proposed public offering in United States

* ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES

BRIEF-Argenx Files For Offering Of Up To $150 Mln American Depositary Shares

* ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING Source text: (http://bit.ly/2kmUxUi) Further company coverage:

BRIEF-Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110

* TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113

* REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

* ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113

BRIEF-Argenx 9M total comprehensive loss widens to 16.5 million euros

* REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-ArgenX launches Phase II proof-of-concept clinical trial of ARGX-113 for treatment of pemphigus vulgaris

* ARGENX LAUNCHES PHASE II PROOF-OF-CONCEPT CLINICAL TRIAL OF ARGX-113 FOR THE TREATMENT OF PEMPHIGUS VULGARIS

BRIEF-Argenx reaches 50% enrollment in phase 2 clinical trial of ARGX-113

* REG-ARGENX REACHES 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF ARGX-113 IN IMMUNE THROMBOCYTOPENIA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up